Royalty Report: Drugs, Delivery, Pharmaceuticals – Collection: 26627

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Delivery
  • Pharmaceuticals
  • Nutraceutical
  • Supplements
  • Disease
  • Therapeutic
  • Food
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26627

License Grant
The Licensor grants a limited license to use CDT to manufacture, package, ship, distribute and sell the Products to Customers, as defined below, in the United States in accordance with and for the Term of this Agreement (the License).
License Property
Our CDT (Controlled Delivery Technology) platform currently consists of three patented drug delivery technologies for prescription drugs, over-the-counter (OTC) products, and nutraceuticals.  The CDT platform is used in solid oral dosage forms, the preferred route for drug administration. This technology is designed to produce tablets or capsules that release their active agents predictably and programmable over a specified time frame of up to 24 hours.
Field of Use
Licensee manufactures and distributes vitamins and dietary and nutritional supplements for various third party customers.

IPSCIO Record ID: 243442

License Grant
Assignor sells, transfers, assigns and delivers to Assignee all of Assignors right, title and interest in and to the Patent Application and the Intellectual Property.
License Property
The Licensors technology is known as oral extended release dosage form based on the principle of controlled hydration.

The CDT system is used in solid oral dosage forms, the preferred route for drug administration. This technology is designed to produce tablets or capsules that release their active agents predictably and programmably over a specified timeframe of up to 24 hours. We believe we can apply our technology to create significant enhancements to existing pharmaceutical, OTC and nutraceutical products.

Proprietary CDT technology improves upon conventional multiple daily dose immediate release forms of existing products by providing the therapeutic benefits of controlled release drug delivery. In addition, we believe our technology can provide enhanced dosage formats for existing medications that provide superior patient convenience and product differentiation.

Field of Use
The use is for oral extended release dosage.

The technology has allowed Assignor cost-effectively develop formulations for the OTC and nutritional industries, such as  glucosamine, glucosamine/chondroitin, niacin, pseudoephedrine, caffeine, vitamin C, Novasoy®, and other difficult compounds and branded ingredients.

IPSCIO Record ID: 279364

License Grant
Licensor grants to Licensee during the Term of this Agreement as to each particular Product the right and license to practice and use the CDT Rights in the manufacture, marketing, distribution, sale and use of the Products in the U.S., including the right to manufacture or have manufactured, market, distribute and sell to third parties. Licensee shall have the right to sublicense the foregoing rights to third parties, in a single tier only, to the extent reasonably necessary to supplement the manufacturing and distribution capabilities of Licensee, subject to the prior approval of Licensor, which shall not be unreasonably withheld.
License Property
Product means any of the Dietary Supplement products listed on this Agreement that use the CDT Rights or any additional Dietary Supplement product using CDT Rights that is added to this Agreement in accordance with the provisions of this Agreement. Products shall not include any product which is not a Dietary Supplement.
List of Products
Glucosamine/Chondroitin
Glucosamine/Chondroitin MSM
Glucosamine Complex
EsterC

Controlled Delivery Technology (CDT)

Patent Rights means all rights to (a) the patents and patent applications identified in this Agreement, (b) any other United States patent or patent application that is owned by Licensor as of the Effective Date and that relates directly or indirectly to any CDT Know-How, any Product, or the design, development, manufacture, testing or use of any Product; and (c) any United States patent or patent application that is filed or acquired by Licensor on or after the Effective Date and that relates directly or indirectly to any CDT Know-How, any CDT Improvements, any Product, or the design, development, manufacture, testing or use of any Product.

US Patent No. 6,337,091-Matrix for controlled delivery of highly soluble pharmaceutical agents
US Patent No. 6,090,411 -Monolithic tablet for controlled drug release

CDT Rights means the Patent Rights, the CDT Know-How, the Other Rights, and the CDT Improvements.

Other Rights means (a) the trademarks identified in this Agreement; (b) any other trademark or service mark that is owned by Licensor as of the Effective Date and that relates directly or indirectly to any Patent Right, any CDT Know-How or any Product; (c) any other Proprietary Right that is owned by Licensor as of the Effective Date (other than the Patent Rights and the CDT Know-How) and that relates directly or indirectly to any Patent Rights, any CDT Know-How, or any Product, (d) any Proprietary Right that is developed or acquired by Licensor on or after the Effective Date (other than any such right that becomes part of the Patent Rights, CDT Know-How, or the CDT Improvements) and that relates directly or indirectly to any Patent Right, any CDT Know-How, any CDT Improvement or any Product; and (e) all goodwill of Licensor associated with the foregoing.

The trademarks identified on this Agreement have been duly registered in the U.S. Patent and Trademark Office. None of the trademarks included in the Other Rights is or has been involved in any opposition or cancellation proceeding, and, to the best of Licensors knowledge, there is no basis for the commencement of any such proceeding. To the best of Licensors knowledge, there are no trademarks owned by third parties that are confusingly similar or dilute any of the trademarks included in the Other Rights.

1. CDT Controlled Delivery Technology trademark with Federal Registration Serial Number 78261152.
2. CDT trademark with Federal Registration Number 2507519.

Field of Use
Licensor's CDT technology to Perrigo for the manufacture, marketing, distribution, and sale of specific dietary supplements.

Licensor's innovative proprietary and patented Controlled Delivery Technology (CDT®) drug delivery technologies enable us to formulate tablets or capsules that release their active agents predictably and programmably over a specified timeframe of up to 24 hours. Our CDT technology platform is designed to reduce the frequency of drug administration, improve the effectiveness of the drug treatment, ensure greater patient compliance with a treatment program, and reduce side effects or increase drug safety. In addition, our amino-acid technology can be incorporated into oral formulations to increase the solubility characteristics of previously non-soluble and sparingly soluble drugs without employing costly micro-milling and coated particle technologies.

IPSCIO Record ID: 243441

License Grant
The parties agree that the Original License should be further amended and restated in its entirety.

The University grants a world-wide exclusive license under patent rights and technical information, with the right to grant sub licenses, to make, have made, use, sell, offer for sale, export, import and otherwise deal with Licensed Product. This license shall be perpetual.

License Property
The Patent Application 08/958,470 and technical information related thereto, are for application thereof to dietary supplements and pharmaceutical products, including over-the-counter products, prescription drugs, OTC drugs and generic drugs.

The Product shall mean
– any dietary supplement,as defined in the 1994 Dietary Supplement and Health Education Act;
– any drug which can be purchased by the general public without a prescription, referred to as an OTC Drug; and,
– any prescription drug, whether existing at the time of this Agreement or yet to be discovered.

Field of Use
The technology is for application to dietary supplements and pharmaceutical products, including over-the-counter products, prescription drugs, OTC drugs and generic drugs.

The new technology has been shown to be rugged and robust during in-vitro studies on a wide range of established pharmaceuticals, such as nifedipine, theophylline, propanolol, diltiazem, and verapamil, as well as OTC and nutritional supplements such as pseudoephedrine, glucosamine and niacin.

Licensee has applied materials science, colloid chemistry and biopharmaceutics in the development of these simple monolithic matrix systems collectively referred to as 'self-correcting matrix delivery systems.'
These approaches use the conventional tableting technologies to form swellable, erodible matrix tablets, caplets or capsules that can potentially yield first-order, bimodal and zero-order drug release profiles. In addition any combinations of soluble, highly soluble, insoluble, low drug dose, high drug load and drug combinations can be easily formulated with these technologies.

IPSCIO Record ID: 200

License Grant
The Licensor, a Delaware corporation, entered into a License Agreement with a newly formed Arizona limited liability company, providing the Licensee with exclusive rights in Canada to manufacture and sell four extended release dietary supplements using the Licensor's proprietary CDT® drug delivery platform.  In addition, the Licensee was granted the rights to manufacture and sell two of such products in the United States on a nonexclusive basis.
License Property
Products
Glucosamine/Chondroitin (24 hour)
Calcium (600 mg) with Vitamin D (500 IU) (24 hour)
Vitamin C mineral ascorbate (500 mg of Ascorbic Acid) (12 hour)
Glucosamine/Chondroitin/Boswellia Serrata/Hyaluronic Acid

Canadian Patent No. 2,323,102 (Monolithic Tablet for Controlled Drug Release) 2. Canadian Patent No. 2,459,014 (Amino Acid Modulated Extended Release Dosage Form)  A controlled release drug delivery tablet for improving linearity of drug delivery over a sustained period of time comprising a hydrophilic swellable matrix a pharmaceutically effective amount of an active agent having a degree of solubilization that is substantially independent of pH over a pH  in the range of pH 1.5 to pH 7.5 dispersed in said matrix, and  a salt selected from the group consisting of sodium chloride, sodium bicarbonate, potassium bicarbonate, sodium citrate, sodium  bisulfate, sodium sulfite, magnesium sulfate, calcium chloride, potassium chloride, sodium carbonate-and a binary salt system comprising at least  two of said salts, said salt being dispersed in said matrix at a concentration which,  upon exposure of the tablet to an aqueous medium, causes hardened  boundary around the periphery of the matrix, said boundary subsequently  progressing inwardly toward the center of the tablet as the aqueous  medium permeates the matrix, said hardened boundary controlling the  rate at which said active agent is released from the tablet, the release rate  of the tablet being substantially independent of the pH of the surrounding  environment, with the provisos,  said tablet does not include polyacrylic acid or a pharmaceutically  acceptable salt thereof, and  said tablet is a monolithic tablet which is a compressed blend of  homogeneous powders comprising said hydrophilic matrix, said active  agent and said salt.

IPSCIO Record ID: 422

License Grant
The University grants to Company a world-wide exclusive license under Patent Rights and Technical Information, with the right to grant sublicensees, to make, have made, use, sell, offer for sale, export, import and otherwise deal with Licensed Product,  for application thereof to dietary supplements and pharmaceutical products, including over-the-counter products, prescription drugs, OTC drugs and generic drugs.
License Property
Product shall mean (i) any dietary supplement (as defined in the 1994 Dietary Supplement and Health Education Act) (referred to herein as a Supplement); (ii) any drug which can be purchased by the general public without a prescription (referred to herein as OTC Drug); and (iii) any prescription drug (whether existing at the time of this Agreement or yet to be discovered).

Patent Application 09/037,096 and PCT Application PCT/US99/04508 related thereto, for application thereof to dietary supplements and pharmaceutical products, including over-the-counter products, prescription drugs, OTC drugs and generic drugs.

IPSCIO Record ID: 338651

License Grant
Licensor of Ireland grants the Licensee, also of Ireland, an exclusive, sublicensable license, solely in the field in the territory to use the Licensor technology, including intellectual property rights to sell and market and exploit the regulatory filings for the products in the field in the territory
License Property
LiquiTime® is a drug delivery platform for modified, extended and controlled release of liquid oral drugs.

Licensor has technology called Liquitime that may be used for developing modified/controlled release oral pharmaceutical products in a liquid suspension formulation.

The patent is titled Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s).

Field of Use
Licensee has licensed rights to the LiquiTime® drug delivery platform for the U.S. Over-the-Counter (OTC) drug market.

The exclusive license includes Licensor’s LiquiTime® Ibuprofen and LiquiTime® Guaifenesin oral suspensions; ibuprofen, an anti-inflammatory and Guaifenesin, an expectorant.  These are the initial products.

IPSCIO Record ID: 27061

License Grant
The Company has previously agreed to pay royalties to CONSULTANT, a member of the Company's Board of Directors, in recognition of the patents developed by CONSULTANT for TIMERx.
License Property
The Company has developed the TIMERx delivery system, a novel drug delivery technology, to address the limitations of currently available oral controlled release delivery systems. The Company believes that the TIMERx system is a major advancement in oral drug delivery that represents the first easily-manufactured oral controlled release drug delivery system that is applicable to a wide variety of drug classes, including soluble drugs, insoluble drugs and drugs with a narrow therapeutic index. The Company is utilizing the TIMERx system to formulate generic versions of branded controlled release drugs, controlled release formulations of currently-marketed.

The TIMERx drug delivery system is a hydrophilic matrix combining primarily a heterodispersed mixture, usually polysaccharides xanthan and locust bean gums, in the presence of dextrose. The physical interaction between these components works to form a strong, binding gel in the presence of water. Drug release is controlled by the rate of water penetration from the gastrointestinal tract into the TIMERx gum matrix, which expands to form a gel and subsequently releases the active drug substance. The TIMERx system can precisely control the release of the active drug substance in a tablet by varying the proportion of the gums, together with the third component, the tablet coating and the tablet manufacturing process. Drugs using TIMERx technology are formulated by combining the active drug substance, the TIMERx drug delivery system and additional excipients and compressing such materials into a tablet.

1)  Directly compressible sustained release excipient.

2)  Sustained release excipient and tablet formulation.

3)  Compressible sustained release solid dosage forms.

4)  EPO Application No. 89309518.2; filed September 19, 1989.

5)  Australian Patent Application No. 43057/89

6)  Japanese Patent Application No. 1-510135

7)  Irish Patent Application No. 2968/89

8)  Canadian Patent Application No. 611,700

9)  Verapamil Tablet Application, Serial No. 736,031 & EPO PCT Applications.

10)  2 U.S. Applications on Bi-modal release.

IPSCIO Record ID: 7576

License Grant
Canadian Licensor hereby grants to the Canadian Licensee, an exclusive worldwide, perpetual license under the Patents and the Licensed Know-How, with such exclusivity being limited to the right to and for the sole purpose the Licensed Application ('License').  The Oral Dissolving Technology is exclusively available to the Canadian Licensee through the License Agreement.
License Property
'Product' shall mean Sildenafil Citrate.

An orally disintegrating tablet or orodispersible tablet (ODT) is a drug dosage form available for a limited range of over-the-counter and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole.

'Licensed Patents' shall mean Intellectual Property solely relating to the Product and US Patent Application 2007/01.90144 (Novel formulation for sublingual drug delivery and use thereof) and all corresponding know-how, patents, patent applications, continuation applications, continuation, etc.

Field of Use
'Field of Use' shall mean oral dissolving technology (sublingual) delivery of the Product.

The first product the Licensee will develop with this technology is sublingual sildenafil. This therapy is used for erectile disfuction.

The Licensee is to complete the required studies and regulatory tasks to commercialize products using the oral dissolving technology and is responsible for any all clinical trials related to the development of products using ODT technology.

IPSCIO Record ID: 291115

License Grant
Licensor of Ireland grants to the Licensee, an entity formed by the Licensor and Licensee parent, for the term of the Agreement an exclusive license, with the right to grant sublicenses, for the territory to clinically test, register, have manufactured in accordance with the terms of this Agreement, to package, use, promote, distribute and sell the product  as a prescription medicine.

Licensor grants a non-exclusive license, with the right to grant sublicenses, in the territory for the term to use the Licensor trademark upon or in relation to the product.

License Property
Product shall mean the encapsulated SODAS® drug specific dosage forms in not more than four dosage strengths not exceeding 180mg.

The drug specificed for this agreement is Once-daily oral morphine capsules, containing SODAS® beads.

The trademark shall mean SODAS®.

The Product to be supplied to Licensee by Licensor shall be in the form of bulk two-piece hard gelatin capsules containing microparticulate SODAS® particles.

SODAS® (Spheroidal Oral Drug Absorption System) is Licensor’s Multiparticulate drug delivery system. Based on the production of controlled release beads, the SODAS® technology is characterized by its inherent flexibility, enabling the production of customized dosage forms that respond directly to individual drug candidate needs.

Field of Use
The license is  for a controlled release oral morphine pain relief product.

Licensor is knowledgeable in the development of drug specific dosage forms and has developed a unique range of delivery systems designed to provide newer and better formulations of medicaments,

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.